biotech / news / / CNBC
Novo Nordisk's Wegovy pill appears to be expanding the obesity treatment market.
Novo Nordisk's Wegovy pill has attracted over 600,000 prescriptions within three months of launch.
KEY POINTS
- The pill is expanding the obesity treatment market by appealing to patients previously deterred by injections.
- Wegovy pill's entry price of $149 per month is among the lowest for GLP-1 therapies.
- Some patients report early weight loss, but effectiveness and tolerability vary widely by individual and dose.
- Lilly's newly approved Foundayo pill may capture market share due to fewer dietary restrictions than Wegovy.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →